Article Details

BioCryst Begins Patient Enrollment in REDEEM-1 Pivotal Trial Evaluating BCX9930 as Oral ...

Retrieved on: 2022-01-08 22:33:00

Tags for this article:

Click the tags to see associated articles and topics

BioCryst Begins Patient Enrollment in REDEEM-1 Pivotal Trial Evaluating BCX9930 as Oral .... View article details on HISWAI: https://pipelinereview.com/index.php/2022010880112/Small-Molecules/BioCryst-Begins-Patient-Enrollment-in-REDEEM-1-Pivotal-Trial-Evaluating-BCX9930-as-Oral-Monotherapy-for-Patients-with-PNH.html

Excerpt

Additionally, the company is initiating a proof-of-concept trial of BCX9930 ... PipelineReview.com is powered by La Merie Business Intelligence La ...

Article found on: pipelinereview.com

View Original Article

This article is found inside other Hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up